Star Therapeutics
Developing life-changing therapies for rare diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | $90.0m Valuation: $500m | Series C | |
| Total Funding | 000k | ||
Related Content
Star Therapeutics focuses on developing life-changing therapies for rare diseases, addressing the needs of millions of patients worldwide. Operating in the biopharmaceutical sector, the company targets approximately 7,000 rare diseases, of which only about 650 have FDA-approved treatments. Star Therapeutics employs a business model centered around the development of first-in-class antibody therapeutics built on novel biology. The company generates revenue through the research, development, and eventual commercialization of these therapies. Star Therapeutics serves patients with rare diseases, healthcare providers, and the broader medical community. The company is committed to innovation and collaboration, fostering a culture of creative and forward-thinking professionals.
Keywords: rare diseases, antibody therapeutics, biopharmaceutical, FDA-approved, novel biology, life-changing therapies, innovation, collaboration, healthcare, commercialization.